Manufactures active pharmaceutical ingredients and formulations for regulated markets, demerged from Strides Pharma Science.
Manufactures active pharmaceutical ingredients and formulations for regulated markets, demerged from Strides Pharma Science.
In one line: A regulated-market API/formulations exporter.
Moat: narrow (regulatory licence). US FDA/EU-approved manufacturing plants support long-term regulated market supply contracts.
Headquarters: Bengaluru, India · Employees: 3,950
Size Alivus Life Sciences (ALIVUS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.90B, the 392nd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,445 on 18 Nov 2026.
Performance Over six months the shares gained 36.1%, against -7.3% for the median peer and +3.8% for the India market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 8.2% over the last twelve months (peer median +11.8%); the operating margin is 31.3% (peer median 16.6%).
Valuation It trades at 23.8× forward earnings against a peer median of 16.9× (7th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 10.8 points above its cost of capital (12.8% WACC).
Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹26.8B | ₹25.4B | ₹23.7B | ₹22.7B | ₹21.5B |
| Revenue growth | — | +7% | +4% | +6% | — |
| Gross profit | ₹12.7B | ₹8.77B | ₹7.64B | ₹7.40B | ₹7.11B |
| EBITDA | ₹9.23B | ₹7.95B | ₹6.82B | ₹6.74B | ₹6.39B |
| Net income | ₹6.70B | ₹5.64B | ₹4.86B | ₹4.71B | ₹4.67B |
| Free cash flow | n/a | ₹2.59B | ₹2.45B | ₹2.97B | ₹1.59B |
| Capital expenditure | n/a | ₹3.07B | ₹1.66B | ₹1.29B | ₹1.70B |
| Total debt | ₹529M | ₹568M | ₹566M | ₹171M | ₹194M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Alivus Life Sciences ALIVUS.NS | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% |
| Strides Pharma Science STAR.NS | $946M | -17% | +11% | 14% | 15.9× | 17.6% |
| Aurobindo Pharma AUROPHARMA.NS | $11.0B | +19% | +14% | 15% | 22.3× | 21.1% |
| Cipla CIPLA.NS | $12.2B | +1% | -1% | 13% | 29.1× | 28.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALIVUS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.9% | +1.7% | 3rd highest of 21 |
| 6-month return | +36.1% | -7.3% | 3rd highest of 21 |
| Distance from 52-week high | -8.2% | -27.6% | highest of 21 |
| Revenue growth (TTM) | +8.2% | +11.8% | 8th lowest of 20 |
| Operating margin | 31.3% | 16.6% | 3rd highest of 20 |
| Forward P/E | 23.8× | 16.9× | 7th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 20.1% | 3.3% | 3rd most demanding of 13 |
| Growth delivered (Del g) | +6.2% | +8.6% | 5th lowest of 13 |
| Hurdle (Req g minus delivered) | +13.9 pp | -12.1 pp | 2nd most demanding of 13 |
| ROIC minus cost of capital | +10.8 pp | +0.1 pp | 5th highest of 20 |
| EV / EBITDA | 18.2× | 16.4× | 5th most expensive of 11 |
| Net debt / EBITDA | -1.0× | 1.4× | 3rd least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 13.0× | 5.4% | +29.1% |
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 15.7× | -6.0% | +7.4% |
| Eris Lifesciences ERIS.NS | India | $1.98B | 0% | +11% | 26% | 27.9× | 26.3% | +20.9% |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% | +4.2% |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |